ArticleNature genetics2009
TMPRSS2-ERG and PTEN loss in prostate cancer.
Article in Nature genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Global meta-analysis of transcriptomics studies.PloS one · 2014Pooled it
- Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.World journal of urology · 2024Trial
- A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.Investigational new drugs · 2015Trial
- Article
- Chromoplexy: A Pathway to Genomic Complexity and Cancer Development.International journal of molecular sciences · 2025Review
- The Expression of Proto-OncogeneInternational journal of molecular sciences · 2022Review
- Tumor Suppressor Role and Clinical Significance of theDisease markers · 2022Article
- The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.International journal of molecular sciences · 2021Review
- Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors.Cell death & disease · 2020Article
- Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer.Oncology letters · 2020Article
- The association of diabetes with risk of prostate cancer defined by clinical and molecular features.British journal of cancer · 2020Article
- Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.BMC cancer · 2020Article
- Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.World journal of urology · 2020Article
- The oncogenic transcription factor ERG represses the transcription of the tumour suppressor geneOncology letters · 2017Article
- Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.Oncotarget · 2017Article
- Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG.Vascular pharmacology · 2016Review
- Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.Oncotarget · 2016Article
- Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two studies show that the common recurrent gene fusion between TMPRSS2 and ERG promotes prostate cancer in both mouse and humans when PTEN is concurrently lost. In human prostate cancer, the presence of both these aberrations may be indicative of poor prognosis, suggesting that preclinical therapeutic research should target both of these pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.